Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 1/20 | 0.69 |
| ▸ | ERN1 | O75460 | 1/20 | 0.69 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.69 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | BCR | P11274 | 1/20 | 0.56 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.53 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.53 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6372773 | 1.00 | TLR2 (0.69) | TLR2ERN1TLR1TLR6MAPT | |
| SCHEMBL9900345 | 0.83 | NFE2L2 (0.61) | MAPTKDM4ENPC1MAPK1RAB9A | |
| SCHEMBL29393422 | 0.83 | NFE2L2 (0.61) | MAPTKDM4ENPC1MAPK1RAB9A | |
| SCHEMBL43264 | 0.83 | NFE2L2 (0.61) | MAPTKDM4ENPC1MAPK1RAB9A | |
| SCHEMBL228813 | 0.83 | NFE2L2 (0.61) | MAPTKDM4ENPC1MAPK1RAB9A | |
| SCHEMBL31004887 | 0.83 | NFE2L2 (0.61) | MAPTKDM4ENPC1MAPK1RAB9A | |
| SCHEMBL18570324 | 0.82 | CDK4 (0.50) | TLR2ERN1TLR1TLR6MAPT | |
| SCHEMBL16004 | 0.82 | ERN1 (1.00) | TLR2ERN1TLR1TLR6MAPT | |
| SCHEMBL929734 | 0.82 | ERN1 (1.00) | TLR2ERN1TLR1TLR6MAPT | |
| SCHEMBL30485148 | 0.82 | ERN1 (1.00) | TLR2ERN1TLR1TLR6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124630-A1 | FLAVOUR IMPROVING SUBSTANCES | Givaudan Nederland Services B.V. (NL) | 2009-12-02 | — | — | EP | claimed |
| WO-2008105652-A1 | FLAVOUR IMPROVING SUBSTANCES | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2008-09-04 | — | — | WO | claimed |
| EP-2223299-B1 | HOLOGRAPHIC RECORDING MEDIUM | SOUTHBOURNE INVEST LTD (GB) | 2015-03-11 | — | — | EP | disclosed |
| US-8435701-B2 | Holographic recording medium | SOUTHBOURNE INVESTMENTS LTD. (GB) | 2013-05-07 | — | — | US | disclosed |
| EP-2223299-A1 | HOLOGRAPHIC RECORDING MEDIUM | Southbourne Investments Ltd. (GB) | 2010-09-01 | — | — | EP | disclosed |
| EP-2124630-A1 | FLAVOUR IMPROVING SUBSTANCES | Givaudan Nederland Services B.V. (NL) | 2009-12-02 | — | — | EP | disclosed |
| EP-2124630-A1 | FLAVOUR IMPROVING SUBSTANCES | Givaudan Nederland Services B.V. (NL) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009067788-A1 | HOLOGRAPHIC RECORDING MEDIUM | SOUTHBOURNE INVESTMENTS LTD. (GB) | 2009-06-04 | — | — | WO | disclosed |
| WO-2008105652-A1 | FLAVOUR IMPROVING SUBSTANCES | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008105652-A1 | FLAVOUR IMPROVING SUBSTANCES | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2008-09-04 | — | — | WO | disclosed |
| CN-1253423-C | Process for production of aspartyl dipeptide ester derivative, novel production intermediate therefor, and process for production thereof | AJINOMOTO KK (JP) | 2006-04-26 | — | — | CN | disclosed |
| US-20050175755-A1 | Process for production of aspartyl dipeptide ester derivative, novel production intermediate therefor, and process for production thereof | AJINOMOTO CO., INC. (JP) | 2005-08-11 | — | — | US | disclosed |
| CN-1566058-A | Process for production of aspartyl dipeptide ester derivative, novel production intermediate therefor, and process for production thereof | AJINOMOTO KK (JP) | 2005-01-19 | — | — | CN | disclosed |
| US-6794531-B2 | ARTIFICIAL SWEETENER | AJINOMOTO CO., INC. (JP) | 2004-09-21 | — | — | US | disclosed |
| US-20040176472-A1 | Process for production of aspartyl dipeptide ester derivative, novel production intermediate therefor, and process for production thereof | AJINOMOTO CO., INC. (JP) | 2004-09-09 | — | — | US | disclosed |
| CN-1378559-A | Process for producing aspartyl dipeptide ester derivative, novel production intermediate therefor, and process for producing the intermediate | AJINOMOTO KK (JP) | 2002-11-06 | — | — | CN | disclosed |
| US-20020133037-A1 | Process for production of aspartyl dipeptide ester derivative, novel production intermediate therefor, and process for production thereof | AJINOMOTO CO. INC (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1231215-A1 | PROCESS FOR THE PRODUCTION OF ASPARTYLDIPEPTIDE ESTER DERIVATIVES, NOVEL INTERMEDIATES THEREFOR AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES | Ajinomoto Co., Inc. (JP) | 2002-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133037-A1 | Process for production of aspartyl dipeptide ester derivative, novel production intermediate therefor, and process for production thereof | DPP4, DNPEP, IAPP | TLR2 3506/4885ERN1 1521/4885TLR1 1899/4885 |
| US-20040176472-A1 | Process for production of aspartyl dipeptide ester derivative, novel production intermediate therefor, and process for production thereof | DPP4, DNPEP, IAPP | TLR2 3506/4885ERN1 1521/4885TLR1 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.